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Background: Deficiency of the enzyme G6PD (G6PDd) is caused by mutations in the gene G6PD, which plays an
important role in protecting the red blood cell against oxidizing agents; it is linked to chromosome X, and it may
affects both sexes. The clinically relevant manifestations, such as acute haemolytic anaemia, mainly occur in men,
however. The 8-aminoquinoline primaquine, which is the medication used in the radical treatment of malaria
caused by Plasmodium vivax, represents the main factor that triggers complications associated with G6PDd. The
current study aims to estimate the costs of G6PDd among male individuals infected by P. vivax in the Brazilian
Amazon.
Methods: This is an economic analysis developed within the Brazilian National Health System perspective for the
years of 2009, 2010 and 2011. Direct medical and non-medical costs were estimated for G6PDd in the Brazilian
Amazon, considering among those suffering from the deficiency the costs of diagnosing infection by P. vivax, its
treatment and severe adverse events that require hospitalization and were connected to the use of primaquine.
Results: The estimates of the average costs of diagnosing vivax malaria, of its treatment and of severe adverse
events after using primaquine among the carriers of G6PDd, over the three evaluated years, corresponded to US$
739,410.42; US$ 2,120.04 and US$ 4,858,108.87, respectively. The results indicate that the average total cost in the
study period corresponded to US$ 5,599,639.33, varying in accordance with the sensitivity analysis between US$
4,439,512.14 and US$ 6,702,619.24.
Conclusion: The results indicate that the use of primaquine among men with G6PDd who are infected by P. vivax
represents a heavy burden on the public health service of Brazil.
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Economic analysisBackground
The enzyme glucose-6-phosphate dehydrogenase (G6PD)
exerts an important role in protecting the red blood
cell from oxidizing agents, being fundamental for the
neutralization of the toxic products of oxygen origin-
ating principally from oxidizing drugs and from infec-
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unless otherwise stated.resulting in haemolysis [1]. G6PD deficiency (G6PDd) is a
genetic disease caused by mutations in the gene that codi-
fies the enzyme. Currently, 186 mutations are known that
produce various functional manifestations, both biochem-
ical ones and phenotypical ones [2,3]. The gene for G6PD
is situated in the telomeric region of the long arm of the X
sex chromosome (band Xq28), and it can affect both
sexes, but the clinically important manifestations occur
mainly in male individuals [4,5]. In Latin America, prima-
quine (PQ), an 8-aminoquinoline used in the radical treat-
ment of the infection (against liver hypnozoites) caused by
Plasmodium vivax, represents the main agent associated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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patients with G6PDd [5,6].
Cases of G6PDd are widely distributed in countries
considered endemic for malaria, with an estimate of 353
million people affected, constituting a general prevalence
of 8%, and of whom 220 million are men [7]. A greater
prevalence is observed in some regions of Sub-Saharan
Africa, followed by Asia and Latin America [7]. In Brazil,
the nine states that compose the Brazilian Amazon con-
centrate more than 99% of the cases of malaria diagnosed,
with 900,000 new cases having been reported between
2009 and 2011, of which 85% are P. vivax malaria [8]. In
this region, the estimated prevalence of G6PDd or the
male sex is 4.5%, with a predominance of the African vari-
ant [9]. Various cases of haemolysis induced by PQ have
been reported in the Brazilian Amazon. The problem
should be dealt with by health authorities [5,10], princi-
pally at this moment in which regional and international
efforts are being harnessed to reduce mortality caused by
malaria [11]. In infections caused by P. vivax, most para-
sites develop and rapidly leave the liver, but some, named
hypnozoites, remain latent in the hepatocytes and will
later cause a relapse [12,13]. In this context, PQ is cur-
rently the only licensed drug that is capable of combating
hypnozoites [13,14].
In Brazil, the public health service, oriented by the
National Program for the Prevention and Control of
Malaria [Programa Nacional de Prevenção e Controle da
Malária (PNCM)], is responsible for the diagnosis and
treatment of malaria throughout the whole country.
The PNCM does not include testing for G6PDd in its
routine, and it recommends the use of PQ for all pa-
tients infected by P. vivax, except for pregnant women
and children under six months of age [12]. In this re-
spect, studies indicate that the use of an 8-aminoquinoline
for someone bearing G6PDd may result in severe an-
aemia, kidney failure and death as a result of haem-
olysis [4,15]. Thus, as health professionals do not know
if the individuals being treated with PQ are or are
not G6PDd, some bearers of the deficiency receive
the medication and develop complications, generating
a resulting demand for resources from the public health
system.
In Latin America, the adoption of public policies fo-
cused on the male population may be more efficient in re-
ducing haemolysis induced by PQ because the cases in
females are rare [5]. However, due to the difficulty of
obtaining information, especially related to hospitalization,
there are no studies in the literature that evaluate the cost
of G6PDd regarding strategies that recommend the use of
PQ in treating vivax malaria. This knowledge is essential
as a basis for discussions related to the adoption of safer
and more effective public policies for malaria control in
Brazil. The present study estimated for the first time thecosts of G6PDd among male individuals infected by
P. vivax in the Brazilian Amazon.
Methods
Study design
This is an economic analysis developed within the
Brazilian National Health Service perspective (Sistema
Único de Saúde - SUS) for the years of 2009, 2010 and
2011. Direct medical and non-medical costs were esti-
mated for G6PDd for the Brazilian Amazon, considering
the male individuals suffering from malaria and carrying
G6PDd. Costs were calculated for the diagnosis and treat-
ment of vivax malaria and for the severe adverse events
associated with the use of PQ. The costs were obtained in
the Brazilian currency (the real, R$) and converted into
American dollars (US$), using the mean exchange rate for
the years under study.
The Brazilian Amazon is composed of 775 municipal-
ities distributed in nine states (Acre, Amapá, Amazonas,
Maranhão, Mato Grosso, Tocantins, Rondônia, Roraima and
Pará), corresponding to an area of land of 5,109,812 km2,
covering about 60% of Brazilian territory. In the region
there are about 21 million inhabitants, with a demo-
graphic density of 4.14 inhabitants/km2, which is consid-
ered the lowest in Brazil [16]. In the years evaluated, on
average 502 municipalities reported cases of vivax malaria
among male individuals [8].
Assumptions for the costs of G6PDd among male
individuals infected by P. vivax in the Brazilian Amazon,
2009, 2010 and 2011
Diagnosis and treatment of vivax malaria among carriers
of G6PDd:
– Diagnosis of vivax malaria: performed by blood
microscopy test, using the Walker method of thick
blood smear;
– Microscope and microscope maintenance: considered
as one microscope and one maintenance per year per
reporting unit, assuming that all reporting units
identified in Information System for Epidemiological
Surveillance of Malaria (SIVEP/MALÁRIA) provided
the diagnosis of P. vivax malaria;
– Training of microscopists: one training period per
year per municipality that reported case of vivax
malaria among men;
– Health worker: the cost of diagnosis and treatment
considered the health agent involved in active
demand of new cases and the microscopist involved
in providing the diagnosis and medication. The
monthly salary of the microscopist and health
worker were based on the salary of Amazonas State,
both relating to the auxiliary level career with
workload of 40 hours per week.
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ment with PQ:
– Costs of specialized medical appointment: one
medical appointment specialized in admission and
another after hospital discharge.
– Tests performed before and after hospitalization: all
carrying G6PDd with severe adverse events and
requiring hospital care were submitted to pre-admission
tests. Among them, the patients released from hospital
did further tests during follow-up monitoring.
– Hospital costs, where all patients with severe
adverse effects were hospitalized:
– Professional costs were calculated based on time
spent per patient/day per doctor, nurse and nursing
technician, assuming the average salaries in
Amazonas state;
– Hospital food: six meals a day for each patient,
assuming values of the FMT-HVD, Amazonas State.
Definition of cases and sources of information
Because Brazil does not carry out the test for G6PDd be-
fore starting treatment with PQ [17], as a basis for defin-
ing cases we took the routine implemented at the Dr.
Heitor Vieira Dourado Tropical Medicine Foundation
(FMT-HVD), a reference in malaria treatment and re-
search in Brazil, and fully funded by SUS. It is situated
in Manaus, the capital of Amazonas state, and in 2013
was responsible for dealing with 2,315 cases of malaria,
which represent 31.85% of the 7,268 cases reported inTable 1 Epidemiological parameters in the Brazilian Amazon,
Items
Number of males submitted to thick blood smear test in Brazilian Amazon1
Number of males with G6PDd submitted to thick blood smear test in Brazilia
Number of males submitted to thick blood smear test in Brazilian Amazon b
Number of males with G6PDd submitted to thick blood smear test in Brazilia
active demand4
Number of vivax malaria cases among males
Number of males with G6PDd among those diagnosed with P. vivax5
Number of units that diagnosed cases of vivax malaria
Number of municipalities in Brazilian Amazon that reported cases of vivax m
Number of males hospitalized with G6PDd after treatment with PQ6
Number of deaths attributed to the use of PQ among carrier men of G6PDd
1Number estimated from multiplying the total number of people of both genders,
2Number estimated from the number of males submitted to thick blood smear examin
3Number obtained from multiplying the estimate of males submitted to thick blood sm
4Number estimated from multiplying the number of males submitted to thick blood
prevalence of G6PDd for males (4.5%).
5Number estimated from the total cases of P. vivax malaria among males in Brazilia
6Number estimated from the number of males with G6PDd among those diagnose
males with G6PDd monitored from 2009 to 2011 in the FMT-HVD.
7Number estimated from the number of males hospitalized with G6PDd after treatm
bearers of the deficiency monitored in the FMT-HVD.Manaus [8]. The FMT-HVD emphasizes that patients
should return to the health centre if they develop cho-
luria, fever and jaundice, besides serving as a tertiary
care centre to where complicated cases from all over the
municipality are referred [18]. In summary, number of
admissions in this centre is a close proxy of all cases re-
quiring hospitalization due to severe haemolysis in Ma-
naus and surrounding areas. Thus, based on the routine
described, the costs were calculated from the following
definition for a case: male carriers of G6PDd who asked
for diagnosis of malaria; were diagnosed as new cases of
vivax malaria; used treatment of PQ and evolved symp-
toms compatible with a severe adverse events resulting
from treatment. Adverse events considered severe included
individuals who needed hospitalization, corroborating
the definition presented in a recent review published by
WHO [19]. The epidemiological parameters considered
are presented in Table 1.
The economic data that supported the estimate of
costs (Table 2) were identified in the scientific literature, in
the System for Managing Standard Prices for Procedures,
Medicines and Materials within SUS (SIGTAP) [20], in the
Bank of Prices in Health (BPS) within the Ministry of
Health (MoH) [21], in documents and databanks supplied
by the Brazilian MoH and by the FMT-HVD. The values
not identified in the evaluated years were adjusted for the
years of 2009, 2010 and 2011, based on the official rate of
inflation estimated by the accumulated National Consumer
Price Index (IPCA) [22]. Epidemiological data and service
data were obtained from the SIVEP/MALÁRIA [8],2009, 2010 and 2011
Years
2009 2010 2011 Sources
1,596,725 1,643,714 1,781,812 [8]
n Amazon2 71,853 73,967 80,182 [8] and [9]
y active demand3 878,473 903,808 968,145 [8]
n Amazon by 39,531 40,671 43,567 [8,9]
155,413 173,559 141,803 [8]
6,994 7,810 6,381 [8,9]
1,814 1,797 1,639 [8]
alaria among men 524 511 472 [8]
6,594 7,364 6,016 [8-10]
7 189 211 172 [8-10]
subject to examination, by the proportion of males.
ation in Brazilian Amazon weighted by prevalence of G6PDd for males (4.5%).
ear test by the overall proportion of individuals diagnosed by active demand.
smear test in Brazilian Amazon by active demand weighted by the
n Amazon weighted by prevalence of G6PDd for males (4.5%).
d with P. vivax multiplied by the proportion of hospitalizations (94.29%) among
ent with PQ, multiplied by the proportion of deaths (2.86%) among the
Table 2 Costs of G6PDd in males infected by P. vivax in the Brazilian Amazon, 2009, 2010 and 2011
Items Reference values - base-case (US$)/year Sources
A - Diagnosis of vivax malaria 2009 2010 2011
All males Males with
G6PDd1
All males Males with
G6PDd1
All males Males with
G6PDd1
- Thick blood smear 1,814,409.17 81,648.41 2,202,950.33 99,132.77 2,665,142.63 119,931.42 [24]
- Microscope 1,096,068.22 49,323.07 1,280,603.64 57,627.16 1,303,580.23 58,661.11 [25]
- Microscope maintenance 83,204.59 3,744.21 97,213.02 4,374.59 98,957.22 4,453.08 [30]
- Health workers 3,912,989.04 176,084.51 4,754,380.68 213,947.13 5,889,094.46 265,009.25 [31]
- Annual training (microscopist) 7,223,201.42 325,044.07 8,307,793.49 373,850.70 8,564,439.54 385,399.78 [30]
- Total costs (A) 14,129,872.43 635,844.27 16,642.941.17 748,932.35 18,521,214.09 833,454.64
B – Drug treatment for P. vivax 2009 2010 2011
All males Males with
G6PDd
All males Males with
G6PDd
All males Males with
G6PDd
- Therapeutic scheme 41,284.62 1,857.92 58,635.90 2,638.56 41,415.28 1,863.65 [32]
C – Assistance to carriers of G6PDd
treated with PQ
2009 2010 2011
Males with G6PDd Males with G6PDd Males with G6PDd
- Pre-admission tests 74,659.04 94,701.04 82,037.35 [20,24]
- Medical appointments 66,271.36 83,681.82 72,047.90 [20]
- Hospitalization2 3,530,482.47 4,457,992.22 3,838,217.22 [20]
- Hospital food 432,757.87 580,711.73 538,733.13 [33]
- Health workers 141,826.64 188,506.44 175,245.56 [34]
- Tests performed after hospitalization 64,235.79 81,530.89 70,688.14 [20,24]
- Total costs (C) 4,310,233.17 5,487,124.14 4,776,969.30
- Total costs (A + B + C)3 4,947,935.36 6,238,695.05 5,612,287.59
1Weighted by the prevalence of G6PDd (4.5%).
2In the years evaluated, 19% and 81% of the costs corresponded to hospitalization in ICT and ward, respectively.
3Males with G6PDd.
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mation obtained in the documents and databanks of
FMT-HVD.Estimate of costs
Diagnosis and treatment of vivax malaria among carriers
of G6PDd
The diagnosis of malaria in Brazil is done by blood mi-
croscopy test, using the Walker method of thick blood
smear, as recommended by the MoH [23]. The costs
considered in the diagnostic strategy for vivax malaria
included materials used in the thick blood smear, micro-
scopes, maintenance of microscopes, salaries of micros-
copists and of the community health agents (CHA)
involved in the diagnosis carried out as active demand
and in the training of microscopists.
The cost of a thick blood smear used in the base case
was estimated from the study carried out by Macauley
[24] in the Brazilian Amazon. The costs obtained were
multiplied by the estimate of the number of G6PDd car-
riers who did the test [8], making it possible to obtainthe total cost of the test in accordance with the year
under evaluation.
The cost of a microscope, estimated at US$ 6,272.00
and presented by Oliveira [25], obtained from unpub-
lished information from the Secretariat of Health Sur-
veillance of the MoH (SHS/ MoH), was used by all the
units that provided malaria case reports. The annual
equipment cost for the base case was calculated for a
period of use of 15 years [26], using a discounting rate
of 5% [27,28] and annualization factor of 10.380 [29].
The maintenance costs for one microscope, estimated
to be US$ 46.00, were based on the cost reported by
Oliveira [30], obtained from information from the Malaria
Laboratory at the Evandro Chagas Institute, SHS/MoH.
The total costs of the microscope and its maintenance
were obtained by the product of the unit value multiplied
by the number of units that diagnosed cases of vivax
malaria, in accordance with the year being considered
[8]. At the end, the cost was weighted by the prevalence of
G6PDd [9].
The costs of the salaries for the microscopists and the
health agents were calculated based on a document from
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proportion of positive slides, per Amazon state [8]. It
allowed us to obtain the number of slides carried out per
professional per day, the number of professionals needed
and the total salary by risk stratum, the sum of which cor-
responded to the total cost. Costing on salaries for micros-
copists considered all the male individuals submitted to the
test and costing on health agents only considered those
submitted to diagnosis by active demand [8], given that this
professional essentially works with this strategy. Finally, the
salary costs were weighted by prevalence of G6PDd [9].
The average cost for training the microscopist was ob-
tained from the study published by Oliveira et al. [30],
which used the cost of one training period a year, lasting
40 hours, based on data supplied by Brazilian MoH
and coming from training given to microscopists in the
Brazilian Amazon in 2006 [30]. The cost for all training
periods represents the product of the number of training
periods, considering one per year per municipality that re-
ported a case of vivax malaria among men, in the year re-
ferred to. The final value was weighted by prevalence of
G6PDd [9].
The cost of anti-malarial medicines was based on the
therapeutic scheme stipulated by the MoH (chloroquine
for three days and PQ for seven days) [12] and informed
by the Strategic Input Information System of the SHS/
MoH [32] as a cost of a tablet of PQ for children (5 mg),
of PQ for adults (15 mg) and of chloroquine 150 mg.
Next, the cost of the therapeutic scheme was calculated,
and this was weighted by the proportion of individuals in
the age categories proposed by therapeutic scheme [12].
The total cost with treatment was calculated by multiply-
ing the cost of the therapeutic scheme and the estimate
for total number of cases of vivax malaria in male carriers,
in accordance with the year being evaluated.
Deficiency of G6PD among men infected by Plasmodium
vivax submitted to treatment with PQ
The cost of G6PDd among carriers of P. vivax submitted
to treatment with PQ considered the individual costs of
the specialist medical consultation and laboratory tests
before hospitalization and after release, expenditure on
hospital care, health professionals and hospital food. The
total costs of specialized consultations and of laboratory
tests were estimated considering the number of patients
hospitalized and the number of patients who were re-
leased from hospital in the years under research. The
cost of a specialized medical consultation was obtained in
SIGTAP [20] and did not undergo variations in the period
of this study. Both the set of pre-admission tests and those
carried out after release from hospital were proposed
based on the opinion of specialists at FMT-HVD (see the
next subsection) and identified in SIGTAP [20], except in
the case of the thick blood smear which, as it does notappear in SIGTAP, was obtained in the literature. The
quantitative test for G6PD was included in the set of tests
carried out after hospitalization, with the aim of confirm-
ing the deficiency and supporting the prevention of new
severe adverse events.
The values of hospital care costs paid for by the SUS, by
means of the Authorization for Hospitalization (AIH),
were obtained from SIGTAP [20], considering the hospi-
talizations in the ward for treatment of anaemia due to
G6PDd (CID 10 – D550) and daily costs in the Intensive
Care Unit (ICU), both paediatric (code 080201007–5) and
adult (code 080201009–1). The component corresponding
to professional services was subtracted from the total
values of the daily hospital costs. To calculate the cost of
hospitalization coming from payment of the AIHs, the daily
value was multiplied by the average 4.25 days in the ward
(hospitalization for anaemia due to G6PDd) and the 7.5 days
in the ICU (paediatric and adult, both bearing the same
daily cost, according to SIGTAP [20]) [10], and weighted by
the proportion of individuals hospitalized in the ward (97%)
and in the ICU (6%), observing that 3% of the individuals
were first in the ward and later needed the ICU [10]. The
total cost of hospitalization represents the product of
multiplying the estimated cost of hospitalization and the
estimated number of hospitalized patients.
The cost of hospital food considered that all hospitalized
individuals received the following meals: breakfast, snack,
lunch, snack, dinner and light supper. The calculation of
the cost per patient was obtained by means of multiplying
the cost of a meal, obtained from the chart of prices paid
by the FMT-HVD [33], by the average number of days
spent in hospital, followed by summing the costs per meal.
The salary costs related to hospitalization due to G6PDd
were based on the average salaries in the state of Amazonas
for a doctor, nurse and nursing technician [34]. Using the
monthly salary, the value of an hour’s work was calculated,
and this was multiplied by the estimated number of hours
dedicated to the patient, obtained from data supplied by the
FMT-HVD. The result was weighted by the proportion of
patients hospitalized by G6PDd among those hospitalized
in the FMT-HVD, during the years under study.
Tests performed in carriers of G6PDd with severe adverse
events associated with the use of primaquina
– Pre-admission tests: thick blood smear, complete
blood count, levels of: serum creatinine, blood urea
nitrogen, SGOT and SGPT, total bilirubin and
fractions, complete urinalysis and reticulocyte count.
– Tests carried out after release from hospital: thick
blood smear, complete blood count, levels of: serum
creatinine, blood urea nitrogen, SGOT and SGPT,
total bilirubin and fractions, complete urinalysis and
testing for G6PDd.
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Individual variation of all the costs was carried out, with
the exception of the cost of specialist medical consulta-
tions and the cost of the therapeutic scheme used in the
treatment of vivax malaria, since there were no varia-
tions for medication and consultation over the evaluated
years [20,32]. The values used for the variations were es-
timated using information that came from the literature
or by variation of 20% above and below the base case.
Results
Table 1 contains the epidemiological and service data that
formed the basis for costing on G6PDd among male indi-
viduals infected with P. vivax in the Brazilian Amazon.
During the evaluated period, in fact, no single woman was
hospitalized due to haemolysis following malaria treat-
ment. According to estimates presented in Table 1, the
strategy for using PQ against P. vivax [12] is considered to
have treated 21,185 male carriers of G6PDd between the
years of 2009 and 2011, leading to 19,974 hospitalizations
and 572 deaths.
Costing on G6PDd among men infected by P. vivax
(Table 2) indicates that the cost of diagnosing P. vivax var-
ied between US$ 635,844.27 (2009) and US$ 833,454.64
(2011); the cost of medicinal treatment of P. vivax varied
from US$ 1,857.92 (2009) to US$ 2,638.56 (2010); and the
cost of severe adverse events associated with the use of
PQ among carriers of G6PDd, considering the tests car-
ried out before and after hospitalization, medical consulta-
tions and hospitalizations, varied from US$ 4,310,233.17
(2009) to US$ 5,487,124.14 (2010). For all the evaluated
years, the relative cost provided in Figure 1 indicates the
predominance of costs arising from the assistance to car-
riers of G6PD treated with PQ. The detailed analysis of
sensitivity of the costs can be seen in Additional file 1.
In Table 3, the average costs are presented for the base
case and the variations considered for the three years, for
the same items previously cited (Table 2), as well as theFigure 1 Relative costs of G6PDd in males infected by P. vivax in thetotal cost reached by adding up all the items. The data in-
dicate that the average cost of G6PDd, over the three eval-
uated years, corresponded to US$ 5,599,639.33, varying in
accordance with the analysis of sensitivity between US$
4,439,512.14 and US$ 6,702,619.24.
Discussion
Malaria represents a severe public health problem in
Brazil, being associated with socio-economic problems
and failures in preventive measures and social protection
actions [35,36]. It presents probable repercussions in the
disease-impoverishment-poverty cycle, and is thus consid-
ered one of the diseases associated with poverty world-
wide, impacting negatively on family income, which then
further increases the vulnerability of the affected popula-
tions [37,38]. In recent years, the Brazilian Amazon has
presented a sharp decline in the incidence of malaria
by P. falciparum; however, the number of people in-
fected by P. vivax has not fallen at the same rate [35],
perhaps because the parasite is able to provoke relapses
weeks or months after the initial infection [39]. Between
the years 2009 and 2011, 767,000 cases of vivax malaria
were reported, of which 470,000 occurred in male individ-
uals, affecting mainly men of productive age [8]. However,
the female population and those in other age categories
also suffer from it, especially children between five and
14 years of age, who may do badly at school due to mal-
aria, thus leading to negative economic impacts and a
drop in productivity in the long-term [40].
The high number of cases of vivax malaria is particularly
important because PQ has been adopted as the strategy for
effecting a radical cure of vivax malaria in Brazil, increasing
the risk of severe adverse events and of deaths, since the
use of PQ at a dose of 0.5 mg/kg/day, for seven days, may
cause acute haemolysis among carriers of G6PDd [5,41].
Although the estimates related to the incidence of severe
adverse events and to deaths associated with the use of
PQ continue to be imprecise [19], evidence obtainedBrazilian Amazon, 2009, 2010, 2011.
Table 3 Average cost of G6PDd in male individuals infected with P. vivax and variations in the Brazilian Amazon, 2009,
2010 and 2011
Items Base-case (US$) Lower limit (US$) Upper limit (US$)
Diagnosis of vivax malaria1 739,410.42 532,081.82 920,943.11
Therapeutic scheme1 2,120.04 2,120.04 2,120.04
Assistance to carriers of G6PDd treated with PQ1 4,858,108.87 3,905,310.28 5,779,556.08
Total cost 5,599,639.33 4,439,512.14 6,702,619.24
1The values in the base case and variations represent the average costs in the years considered in the study.
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Afghanistan, Tajikistan and Korea demonstrates that
rigorous management of the risks may minimize their
effects on populations with various degrees of G6PDd [42].
The number of hospitalizations and of deaths presented
was calculated from the proportion of hospitalizations
(94.29%) and of deaths (2.86%) among the carriers of
G6PDd attended in the FMT-HVD [10]. Thus, both pro-
portions represent the situation in a reference centre
for treatment, and this may differ from what happens
in remote areas and small municipalities in the Brazilian
Amazon. In the latter case, the proportion of hospitaliza-
tions may have been over-estimated and the deaths under-
estimated, given that not only are health resources scarce
in these places, but they also present problems of accessi-
bility to health services that offer moderate to high-level
technology.
Currently, tafenoquine is at an advanced stage of develop-
ment and that has presented effectiveness in the prevention
of relapse with just one dose, may be able to achieve the de-
sired elimination of vivax malaria, but the fact that it is an
8-aminoquilonine means that it presents the same chal-
lenge in relation to safety for use with carriers of G6PDd,
reinforcing the discussion about the need to detect the de-
ficiency before starting treatment [6,19,43].
The current research estimated a high number of male
individuals with G6PDd exposed to the use of PQ and
demonstrates that this deficiency may have an important
effect on the need for hospitalization, being associated
also with a significant number of deaths in individuals
infected by vivax malaria. The direct medical and non-
medical costs arising from diagnosis and treatment of
vivax malaria and from the severe adverse events result-
ing from the use of PQ are high for the health service.
There is a predominance observed of costs related to
complications that occur after the use of PQ, especially
those linked to hospitalization, indicating that among
those suffering from the deficiency the severe adverse
events burden the public health system more than the
diagnosis and treatment of vivax malaria. As regards
hospitalization, although assistance provided in the ward
has predominated, the cost arising from 6% of those with
G6PDd who go to intensive care corresponded to 19%
of the total hospitalization costs, demonstrating theimportance of severely ill patients in the context being
researched. The high cost of hospitalization of carriers
of G6PDd was also confirmed in another context. An
economic evaluation of the cost of this deficiency among
Lebanese male newborns identified a cost of US$ 1,450.00
per hospitalization [44]. The average cost presented in
Table 3 may be considered high in the Brazilian context,
where the SUS budget directed towards surveillance,
prevention and control of malaria in 2009, 2010 and 2011
was, respectively, US$ 12,115,577.89; US$ 9,622,159.09
and US$ 9,802,395.21 [45].
Although studies were not identified in the literature
that evaluate the cost of G6PDd in the context under re-
search, there are recent publications that indicate how
urgent it is to carry out economic evaluations on this
topic, highlighting especially the need to estimate the
costs and effectiveness of incorporating rapid diagnostic
tests (RDTs) to detect G6PDd. These should be used at
the point of care before applying PQ [4,6,46], similar to
what has been described in the Brazilian context in rela-
tion to the cost-effectiveness of RDTs for diagnosing
malaria itself [30,47], helping in decision-making on the
incorporation or not of this technology. Currently, two
RDTs to detect G6PDd in field conditions (BinaxNOW®
G6PD and CareStartTM G6PD) have been evaluated in
malaria endemic areas [48,49]. However, there are still
gaps in knowledge about the performance, stability and
costs of RDTs [19].
The acute character of the complication under discus-
sion, associated with the constitutional responsibility of the
SUS to guarantee universal, complete and equitable assist-
ance, means that the costs falling to the SUS constitute im-
portant data. They may be used to help in decision-making
and in the development of other economic studies on the
topic, especially ones aiming to evaluate the strategies for
prevention of severe adverse events, based on the recom-
mendation for diagnosis of G6PDd before using PQ [19].
In this ambit, it is fundamental that research be carried out
in Latin America, aiming to study locally the cost and ef-
fectiveness of tests to detect G6PDd in field conditions to
reduce the cost of hospitalization [46].
Economic evaluations developed in relation to malaria
have become increasingly frequent, especially in Sub-Saharan
Africa, in Asia and in South America. White et al. identified
Peixoto et al. Malaria Journal  (2015) 14:126 Page 8 of 9that the cost of diagnosing a case of malaria ranged from
US$ 0.34 to US$ 9.34, the cost of treating a case of un-
complicated malaria from US$ 2.36 to US$ 23.65 and the
cost of a case of complicated malaria from US$ 15.64 to
US$ 137.87 [50].
This is the first study of the costs of G6PDd in Brazil,
and the results presented here are based on sources of
epidemiological and secondary economic data. It should
be stressed that there is an absence of precise data con-
cerning G6PDd for the whole of the Brazilian Amazon,
which may differ because of the diversity in ethnic origin
in the region. Furthermore, the data on prevalence of
G6PDd, the proportion of individuals hospitalized, the
proportion of deaths, the costs of hospital food and sal-
aries for professionals were obtained in the state of
Amazonas and generalized for the nine states that make
up the Brazilian Amazon. This may have affected the
validity of the cost estimates, although the simulation
carried out in the analysis of sensitivity has demon-
strated that the uncertainties mentioned did not sub-
stantially affect the total cost.
Conclusion
Within the scope of the Brazilian strategy for controlling
vivax malaria, G6PDd represents a serious problem for
public health. It has particularly affected men of econom-
ically productive age who live in vulnerable communities.
As the efforts directed towards controlling and eliminating
malaria are based on using an 8-aminoquinoline, attention
must be paid to the safety of those carrying G6PDd. The
results presented constitute basic evidence in the discus-
sion on the use of PQ without prior testing to detect
G6PDd. It is recommended that a research agenda be
adopted that will evaluate on a regional basis the costs
and accuracy of RDTs to detect G6PDd, with the aim of
checking if it is viable to incorporate these into the health
system’s strategy.
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